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Abstract: This review aims to highlight the recent findings of long non-coding RNAs (lncRNAs) in
liver disease. In particular, we focus on the functions of lncRNAs in hepatocellular carcinoma (HCC)
and non-alcoholic steatohepatitis (NASH). We summarize the current research trend in lncRNAs and
their potential as biomarkers and therapeutic targets for the treatment of HCC and NASH.
Keywords: liver; lncRNA; miRNA; liver cancer; HCC; NASH
1. Introduction
Liver cancer is the second leading cause of cancer-related death globally with an estimated
number of one million cases diagnosed in 2016 and a 5-year survival rate of less than 20% [1–3].
Hepatocellular carcinoma (HCC) accounts for 90% of primary liver cancers and is increasing in
incidence worldwide. Major risk factors for HCC include chronic hepatitis B virus (HBV) and hepatitis
C virus (HCV) infections [1,4], alcohol-induced liver disease, non-alcoholic fatty liver disease (NAFLD),
which was recently proposed to be renamed as metabolic-associated fatty liver disease (MAFLD) [5]
and non-alcoholic steatohepatitis (NASH) [6]. HCC development is recognized as a multistep process
with 70–80% of cases occurring in the context of liver cirrhosis, in which multiple somatic, genomic,
and epigenomic alterations occur along each stage of disease progression [1]. HCCs can be classified by
genomic, epigenomic, and transcriptomic profiling into two major molecular subtypes, each comprising
ca. 50% of HCC patients. The first class, named as the proliferation class, is associated with poor
prognosis, chromosomal instability, and activation of classical oncogenic signaling pathways involved
in cell proliferation and survival. The non-proliferation class of HCC is more heterogenous, is less
aggressive with slower disease progression, and is associated with better prognosis than the proliferation
class tumors [1].
HCC is highly resistant to therapy and thus considered as a difficult-to-treat cancer. For HCC
patients with early-stage disease, potentially curative treatment options (e.g., liver transplantation,
local ablation or surgical resection) are possible [1,4]. However, most HCC patients are diagnosed at
an advanced tumor stage and do not qualify for these treatment options. The multi-target tyrosine
kinase inhibitor (TKI) sorafenib is the first systemic therapy approved for the treatment of advanced
stage HCC and has been shown to extend the median overall survival from 8 to 11 months [1,4].
Improvements in HCC patient outcome has also been reported with other TKIs (i.e., lenvatinib,
cabozantinib, and regorafenib) as well as with nivolumab, which is a monoclonal antibody targeting
the immune checkpoint PD-1 [1]. However, the median overall survival of advanced stage HCC
patients is still only 11–12 months, which underscores the unmet medical need for novel therapeutic
approaches for treatment of HCC.
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NASH is a progressive subtype of NAFLD (MAFLD) characterized by the presence of ballooned
hepatocytes, inflammatory infiltrates, and fibrosis [7,8]. It is a complex and multifactorial disease
that is modulated by several mechanisms including genetic, environmental, metabolic, and gut
microbial factors [7,8]. Genome-wide association studies (GWAS) in large cohorts indicate that
polymorphisms in two genes, patatin-like phospholipase domain–containing 3 (PNPLA3) and
transmembrane 6 superfamily member 2 (TM6SF2), are strongly associated with development of
NAFLD and NASH [7,8]. Furthermore, gut microbiota has been shown to impact host susceptibility to
obesity, hepatic steatosis, NASH, and liver fibrosis, whereas the most important environmental factors
linked to NASH include dietary habits, activity, and socioeconomic factors [7,8].
NASH is strongly associated with obesity and the metabolic syndrome and affects over 6% of the
adult population in the United States. Furthermore, 15–25% of NASH patients develop liver-related
complications, such as cirrhosis and HCC [7–9]. Indeed, NASH is rapidly becoming the leading cause
of end-stage liver disease and liver transplantation [10]. The annual medical costs associated with
NAFLD exceed USD 100 billion in the United States and EUR 35 billion in four European countries
(Germany, France, Italy and the UK); much of which is attributable to NASH [9]. This underscores the
importance of developing new effective and safe therapies for treatment of NASH.
Recent data imply that the human genome is pervasively transcribed and encodes tens of
thousands of long noncoding RNAs (lncRNAs) that play regulatory roles in numerous biological
processes [11–13]. LncRNAs comprise a large and heterogeneous group of transcripts that are longer
than 200 nucleotides (nt) in length, lack an open reading frame, are often expressed at much lower
levels than protein-coding genes, and are less conserved than mRNAs [11,12,14,15]. Many lncRNAs
exhibit highly cell- and/or tissue-specific expression and play important roles as regulators of key
cellular pathways, which makes them potential targets for therapeutic intervention [16,17]. In this
review, we summarize the current understanding of lncRNA functions in the liver. Furthermore,
we review the recent progress on the role of lncRNAs in the pathogenesis of HCC and NASH and
discuss their potential as biomarkers and targets for therapeutic intervention.
2. Molecular Mechanisms of Long Non-Coding RNAs in the Liver
2.1. LncRNAs as Scaffolds for Proteins
To date, several mechanisms of action for lncRNAs have been reported. The most investigated one
is a molecular mechanism in which lncRNAs function as scaffolds for epigenetic factors, especially for
the functional enzymatic component of the polycomb repressive complex 2 (PRC2), the enhancer of zeste
homolog 2 (EZH2). There are few studies in recent years reporting lncRNAs binding to EZH2 in the
liver, such as cancer susceptibility 11 (CASC11) [18], DDX11 antisense RNA 1 (DDX11-AS1) [19], deleted
in lymphocytic leukemia 2 (DLEU2) [20,21], HOXA11 antisense RNA (HOXA11-AS) [22], nuclear
paraspeckle assembly transcript 1 (NEAT1) [23], and Pvt1 oncogene (PVT1) [24] (Figure 1A). The concept
of scaffolds for epigenetic factors has been heavily investigated as chromatin immunoprecipitation
(ChIP) can be performed with ease using kits readily available from commercial vendors. Although it
is popular to identify lncRNA binding to EZH2, it was shown to bind any RNA promiscuously [25–29].
Thus, such mechanism must be investigated carefully.
Besides EZH2, other epigenetic and transcription factors have been identified to bind lncRNAs
to regulate transcription such as: damage-induced long noncoding RNA (DINO), which binds
to p53 to enhance p53 stability in response to cellular stress [30]; and HAND2 antisense RNA 1
(HAND2-AS1), which binds to INO80 complex ATPase subunit (INO80) to induce the expression of
bone morphogenetic protein receptor type 1A (BMPR1A), leading to the activation of BMP signaling [31].
Furthermore, gankyrin-associated lincRNA in hepatocellular carcinoma (Linc-GALH) binds to DNA
methyltransferase 1 (DNMT1) to regulate its ubiquitin status [32], while the long intergenic non-protein
coding RNA 324 (LINC00324) was shown to bind Spi-1 proto-oncogene (SPI1, also known as PU.1) to
regulate the expression of Fas ligand (FASLG) [33]. The lncRNA regulator of Akt signaling associated
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with HCC and RCC (LNCARSR) binds to the Yes1-associated transcriptional regulator (YAP1) to
inhibit its phosphorylation nuclear translocation, resulting in activation of the IRS2/AKT pathway,
leading to increased lipid accumulation, cell proliferation, invasion and cell cycle [34]. The translation
regulatory long non-coding RNA 1 (TRERNA1) binds the euchromatic histone lysine methyltransferase
2 (EHMT2) to dimethylate the promoter of cadherin 1 (CDH1) [35]; TSPOAP1, SUPT4H1 and RNF43
antisense RNA 1 (TSPOAP1-AS1, also known as BZRAP1-AS1) binds to DNA methyltransferase 3 beta
(DNMT3B) to induce methylation of the promoter of thrombospondin 1 (THBS1), resulting in its
inhibition [36] (Figure 1B). Taken together, these studies highlight the fact that transcriptional regulation
via lncRNAs is an important mechanism to be investigated, although careful dissection of the gene
regulatory networks by combining ChIP-seq and other methods (e.g., chromosome conformation
capture techniques [37]) must be conducted in a genome-wide manner to record the influence of such
lncRNAs on a number of genes, as many of these epigenetic and transcription factors (positively or
negatively) regulate not only one but many genes.
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Figure 1. Molecular mechanism of long non-coding R s (lncRNAs). (A) A growing list of lncRNAs
bind to the enhancer of zeste homolog 2 (EZH2). Because of promiscuous RNA binding capability of
EZH2, a large number of lncRNAs have been identified as its binding partner. EED, embryonic ectoderm
development; RBBP4, RB binding protein 4, chromatin remodeling factor; RBBP7, RB binding protein 7,
chromatin remodeling factor; SUZ12, SUZ12 polycomb repressive complex 2 subunit. (B) LncRNAs
binding to epigenetic and transcription factors. The protein–protein inter ctions (PPI) are based on the
information provided by the STRING database [38].
As lncRNAs can be localized in the nucleus as well as in the cytosol, an increasing number of
studies have reported lncRNAs that bind to RNA-binding proteins (RBPs). As the name indicates,
the main func ion of RBPs is to bind single- or double-st anded RNA to regulate its metabolism, stability,
subcellular localization, and translation. Such lncRNAs are often referred to as RBP sponges. In the liver,
the following lncRNAs have been reported to bind RBPs: FAM83A antisense RNA 1 (FAM83A-AS1),
which binds to NOP58 ribonucleoprotein (NOP58) to enhance the mRNA stability of family with
sequence similarity 83 membe A (FAM83A) [39]; and the g stric cancer metastasis-associated long
noncoding RNA (GMAN), which binds to eukaryotic translation initiation factor 4B (EIF4B) to
promote its phosphorylation, resulting in increased mRNA translation of anti-apoptotic proteins [40].
Furthermore, Linc-SCRG1 (XLOC_004166; lnc-Hand2-2:1) was shown to bind the ZFP36 ring finger
protein (ZFP36, also known as tristetraprolin (TTP)) to degrade its mRNA [41], wh reas the long
intergenic non-protein coding RNA 1093 (LINC01093) binds to insulin like growth factor 2 mRNA
binding protein 1 (IGF2BP1) to regulate the translation of oncogene homolog 1 (GLI1) mRNA [42],
and the LncRNA pleiotrophin downstream transcript (lncRNA Ptn-dt) binds to ELAV (embryonic
lethal, abnormal vision)-like 1 (Hu antigen R) (Elavl1, also known as HuR) to repress the expression
of miR-96, resulting in increased expression of anaplastic lymphoma kinase (Alk) [43]. Although it is
attractive to investigate translation control via lncRNAs functioning as RBP sponges, just as epigenetic
and transcription factors, RBPs bind many mRNAs. Thus, genome-wide screening of target mRNAs
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deploying RNA immunoprecipitation followed by next-generation sequencing (RIP-seq) must be
conducted to understand the role of RBP sponges upon manipulation (e.g., gain/loss-of-function) of
such lncRNAs.
2.2. LncRNAs as microRNA Sponges
Recent studies have increasingly focused on lncRNAs as microRNA (miRNA) sponges
(also referred to as, competing endogenous RNAs (ceRNAs)), in which lncRNAs sequester miRNA
activity (Figure 2A). The interest in studying miRNA sponges is in line with the therapeutic potential
of miRNAs, since lncRNAs could be used as an additional layer of post-transcriptional control
of gene expression [44]. Furthermore, over two decades of accumulated research on miRNAs has
generated several experimental approaches (e.g., antimiRs, mimics, luciferase reporter assays for
binding of miRNAs) that can be utilized to further elucidate the functions of lncRNAs. Since 2019,
71 lncRNAs were reported to function as miRNA sponges (Supplementary Table S1). Because the
seed sequences of miRNAs are very short (6~8-mers), it is not surprising that lncRNAs contain
predicted target sites for many miRNAs. For example, the lncRNA colorectal neoplasia differentially
expressed (CRNDE) was suggested to sequester miR-126-5p, miR-33a, and miR-203, which target
BCL2 like 2 (BCL2L2) [45], high mobility group AT-hook 2 (HMGA2) [46], and branched chain amino
acid transaminase 1 (BCAT1) [47] mRNAs, respectively (Figure 2B). Furthermore, the longer a given
lncRNA is, the more likely it is to contain binding sites for miRNAs [48]. For example, maternally
expressed 3 (MEG3) is a maternally expressed, imprinted lncRNA with 49 isoforms (Ensemble database
accession ENSG00000214548) with the longest isoform being 12,998 nt (ENST00000522771). MEG3 is a
well-known miRNA sponge [49]. Since 2019, there have been four studies reporting its function as a
miRNA sponge in the liver by binding to miR-9-5p, miR-21, miR-26b-5p, and miR-214, which target
SRY-box transcription factor 11 (SOX11) [50], LDL receptor related protein 6 (LRP6) [51], platelet derived
growth factor receptor beta (PDGFRB) [52], and activating transcription factor 4 (ATF4) [53] mRNAs,
respectively. Another well-known miRNA sponge, the nuclear paraspeckle assembly transcript
1 (NEAT1) [54] with nine isoforms (ENSG00000245532) with the longest isoform being 22,743 nt
(ENST00000501122), binds to let-7a, miR-22-3p, miR-29b, miR-140, miR-146a-5p, miR-155, miR-335,
and miR-506 [55–62]. With an lncRNA having many isoforms, the research questions should focus
on the identification of isoform-specific function of miRNA sponges, as it is experimentally very
challenging to overexpress an isoform with over 10,000 nt in a stable manner. It should be noted that
the ceRNA hypothesis is still being debated due to the fact that most experimental evidence is based on
expression profiling such as qRT-PCR. Furthermore, studies that have modelled transcriptome-wide
miRNA target site abundance suggest that physiological changes in expression levels of most individual
transcripts, including lncRNAs, are insufficient to modulate miRNA activity [63–66]. Thus, further
research is needed to establish the miRNA sponge (ceRNA) mechanism for lncRNAs.
One miRNA can target many mRNAs [67], and may also modulate multiple lncRNAs. Indeed,
miR-33a-5p, which targets the twist family bHLH transcription factor 1 (TWIST1) and high mobility
group AT-hook 2 (HMGA2), can be sequestered by two lncRNAs, namely, cancer susceptibility 15
(CASC15) [68] and eosinophil granule ontogeny transcript (EGOT) [69], respectively (Figure 2C).
Another example is the lncRNA brain cytoplasmic RNA 1 (BCYRN1) and the lncRNA small
nucleolar RNA host gene 15 (SNHG15), which bind to miR-490-3p targeting POU class 3 homeobox 2
(POU3F2) [70] and histone deacetylase 2 (HDAC2) [71], respectively. The reverse is also possible; that is,
one gene can be targeted by multiple miRNAs [72]. Thus, it is not surprising that an lncRNA functioning
as a miRNA sponge can bind several miRNAs, which target the same gene. For example, the lncRNA
growth arrest specific 5 (GAS5) binds miR-21 [73], miR-23a [74], miR-135b [75], and miR-544 [76],
where both miR-21 and miR-23a target the 3′-untranslated region (3′-UTR) of phosphatase and tensin
homolog (PTEN) [73,74] (Figure 2D). Another example is the signal transducer and activator of
transcription 3 (STAT3), which is targeted by miR-15a-3p, miR-384, and miR-4500, that, in turn, are
sequestered by the lncRNA HOXA11 antisense RNA (HOXA11-AS) [77], CDKN2B antisense RNA 1
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(ANRIL) [78], and small nucleolar RNA host gene 16 (SNHG16) [79], respectively (Figure 2E). Given that
there are 1917 annotated hairpin precursors and 2654 mature sequences of human miRNAs according to
the miRNA database, miRBase [80], it would not be a surprise to find intertwined networks of miRNA
sponges sequestering miRNAs that target the 3′-UTR of the same gene for gene repression. It should
be noted that miRBase has not been updated since October 2018 (Release 22.1); thus, more miRNAs
have likely been identified since then, which may further contribute to more complex intertwined
networks of miRNA sponges as more lncRNAs are discovered to function as such. Furthermore,
it should be stressed that the interaction between lncRNAs and miRNAs stated in this subsection
are restricted to the current findings (since 2019) in the liver. If the information search is extended
to other tissues and time, more lncRNAs functioning as miRNA sponges with their specific targets
can be identified. Taken together, the identification of lncRNAs as miRNA sponges is only at the
beginning of understanding the many potential interactions among lncRNAs, miRNAs, and 3′-UTRs
of protein-coding genes.
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Figure 2. LncRNAs as miRNA sponges. (A) A sc atic illustration of miRNA spo ge mechanism in
the cell. RISC, RNA-induced silencing complex. (B) The lncRNA colorectal neoplasia differentially
expressed (CRNDE). (C) An example of miRNA being sequestered by two lncRNAs. CASC15,
cancer susceptibility 15; EGOT, eosinophil granule ontogeny transcript; HMGA2, high mobility group
AT-hook 2; TWIST1, twist family bHLH transcription factor 1. (D) The lncRNA growth arrest specific 5
(GAS5). Interestingly, GAS5 sequesters miR-21 and miR-23a, which both target phosphatase and tensin
homolog (PTEN) mRNA. BCL2L2, BCL2 like 2; BCAT1, branched chain amino acid transaminase 1;
MMP2, matrix metallopeptidase 2; RUNX3, RUNX family transcription factor 3. (E) An example of
a target mRNA with multiple miRNA binding sites. HOXA11-AS, HOXA11 antisense RNA; ANRIL,
antisense non-coding RNA in the INK4 locus; SNHG16, small nucleolar RNA host gene 16; STAT3,
signal transducer and activator of transcription 3.
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2.3. LncRNAs as Post-Transcriptional Modulators
Besides the above mechanisms of action, other biological roles for lncRNAs have also been
reported. For example, the regulation of STAT3 is important in the liver as its activation is recorded
in liver injuries and diseases [81–83]. Besides lncRNAs functioning as miRNA sponges to regulate
the translation of STAT3 (Figure 2E), the lncRNA Pvt1 oncogene (PVT1) increases the stability of
phosphorylated STAT3 [84]; the lncRNA SLC2A1 antisense RNA 1 (SLC2A1-AS1) competitively binds to
STAT3 to interfere its binding to the promoter of solute carrier family 2 member 1 (SLC2A1, also known
as GLUT1) via forkhead box M1 (FOXM1) [85]; and the lncRNA TPTE pseudogene 1 (TPTEP1) inhibits
the phosphorylation, homodimerization, and nuclear translocation of STAT3 [86]. Taken together,
these recent findings about lncRNA mechanisms should facilitate the further understanding of
pathophysiology of liver, which in turn, contributes to the development of new therapeutic approaches.
3. LncRNAs in HCC
Several lncRNAs have been implicated in the pathogenesis of HCC [87]. For example, the lncRNA
metastasis-associated lung adenocarcinoma transcript 1 (MALAT1), which regulates alternative splicing,
is upregulated in many solid tumors including HCC, and is associated with cancer metastasis and
recurrence [88–91]. Furthermore, MALAT1 was shown to promote cell metastasis by upregulation
of transforming growth factor β-binding protein 3 (LTBP3) in HCC [92]. The H19 gene is paternally
imprinted and encodes an lncRNA that is expressed during development of fetal liver and strongly
down-regulated after birth [93]. H19 is highly expressed in many human cancers [94–96]; however,
its function in HCC appears to be more complex compared to other cancers. Several studies have
proposed that H19 functions as an oncogene, with its activation contributing to the pathogenesis
of HCC. For example, hypoxia has been shown to induce H19 expression in HCC cells, whereas
knockdown of H19 attenuated HCC tumor growth [97]. On the other hand, H19 is also a precursor of
miR-675, and recent studies show that miR-675 promotes tumor progression by repressing twist basic
helix-loop-helix transcription factor 1 (Twist1), implying that the proposed oncogenic role of H19 is
mediated by the biological function of miR-675 [98]. Interestingly, a study investigating the co-operation
of H19 and miR-675 in HCC reported that knockdown of H19 and miR-675 promoted migration and
invasion of HCC cells through the AKT/GSK-3β/Cdc25A signaling pathway [99], suggesting that H19
and/or miR-675 function as tumor suppressors.
The lncRNA taurine up-regulated 1 (TUG1) has been shown to regulate glycolysis and metastasis
in HCC through hexokinase 2 (HK2), and thereby provides a potential therapeutic strategy of targeting
TUG1 for treatment of HCC [100]. The NEAT1 locus is highly conserved and produces two lncRNA
isoforms, an abundant 3.7 kb NEAT1_1 isoform and a 22.7 kb NEAT1_2 isoform, which functions as
a key structural component of nuclear paraspeckles, that are subnuclear bodies composed of RNA
elements [101,102]. A recent study reported that NEAT1 is a bona fide target gene of the tumor suppressor
p53 and established a direct link among NEAT1 paraspeckles, p53 biology, and tumorigenesis [103].
Notably, inhibition of NEAT1_2 was shown to sensitize cancer cells to DNA-damaging chemotherapy,
such as doxorubicin and bleomycin [103], whereas siRNA-mediated knockdown of NEAT1 in HCC
cell lines inhibited proliferation, migration, invasion, and induced apoptosis [104]. The expression
of the lncRNA hepatocellular carcinoma up-regulated long non-coding RNA (HULC) is increased
in HCC [105], and its expression is regulated by the transcription factor CREB (cAMP response
element-binding protein) via interaction with miR-372 [106]. HULC has been shown to contribute
to HCC pathogenesis by deregulating lipid metabolism through a signaling pathway involving the
peroxisome proliferator-activated receptor alpha (PPARA) [107]. In addition, HULC was reported
to function as a miRNA sponge activating epithelial–mesenchymal transition, and promoting HCC
progression and metastasis via the miR-200a-3p/ZEB1 signaling pathway [108].
The lncRNA differentiation antagonizing non-protein coding RNA (DANCR) is overexpressed in
stem-like HCC cells, and binds to the 3′-UTR of β-catenin 1 (CTNNB1) mRNA, thereby blocking by
competitive binding repression of CTNNB1 by miR-214, miR-320a, and miR-199a [109]. This observation
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was confirmed in a mouse HCC model, suggesting that DANCR increases stemness features of HCC
by derepressing CTNNB1 [109]. The lncRNA HOX transcript antisense RNA (HOTAIR) is a part of the
HOXC gene cluster on chromosome 12 and is an example of an lncRNA that functions as a scaffold
and guides epigenetic regulators to genomic loci in trans. HOTAIR promotes silencing by acting as
a scaffold to assemble the PRC2 and the lysine-specific demethylase 1 (LSD1) on the HOXD cluster,
where these protein complexes specifically trimethylate histone H3 on lysine 27 and demethylate H3
on lysine 4, respectively, resulting in epigenetic silencing of HOXD genes [110,111]. HOTAIR is highly
expressed in primary as well as metastatic breast tumors, and high level of expression in primary
breast tumors is a powerful predictor of subsequent metastasis and death [112]. Several studies have
investigated the clinical implications of HOTAIR in HCC. Expression of HOTAIR is significantly higher
in HCC compared to adjacent normal liver tissues [113,114]. HCC patients that overexpress HOTAIR
exhibit a shorter recurrence-free survival compared to patients with low levels of HOTAIR [115,116],
suggesting that HOTAIR could be utilized as a metastatic biomarker for HCC.
4. LncRNAs in NAFLD and NASH
Accumulation of liver fat is a requisite for NAFLD and its progressive subtype NASH. A recent
study showed that the lncRNA brown fat-enriched lncRNA 1 (Blnc1) is strongly upregulated in obesity
and NAFLD in mice and functions as a core component of the LXR/SREBP1c pathway in the regulation
of hepatic lipogenesis [117]. Furthermore, liver-specific ablation of Blnc1 protected the Blnc1 conditional
knockout mice from high fat diet-induced hepatic steatosis and insulin resistance and ameliorated
diet-induced NASH pathogenesis in mice, suggesting that Blnc1 could be a potential therapeutic target
for treatment of NAFLD and NASH [117]. Another recent study identified 89 differentially expressed
lncRNAs in a NASH minipig model [118], whereas several lncRNAs, including the lncRNA functional
intergenic repeating RNA element (Firre), have been shown to regulate adipogenesis [119]. MALAT1
is frequently upregulated in HCC and is associated with cancer metastasis and recurrence [81–84],
as described above. A recent study deployed a systems biology approach to explore lncRNA expression
in the severity of NAFLD, and identified MALAT1 as a potential molecular driver in the pathogenesis
of NASH [120]. Another study profiled lncRNA expression in liver biopsies from NAFLD patients with
normal liver histology, lobular inflammation, and advanced fibrosis, respectively, and found that the
HULC and MALAT1 lncRNAs were upregulated in fibrotic livers relative to normal liver tissue [121].
The C-X-C motif chemokine ligand 5 (CXCL5) was identified as a target for MALAT1, suggesting that
MALAT1 could play a role in the pathogenesis of NAFLD via a chemokine-mediated mechanism [121].
MEG3 encodes an imprinted lncRNA that is frequently lost or downregulated in many human
cancers and has been proposed to function as a tumor suppressor [122]. A systematic analysis of lncRNA
expression in NAFLD and control liver samples found that the levels of MEG3 were significantly
decreased in liver tissues of NAFLD patients [123]. Downregulation of MEG3 in NAFLD was negatively
correlated with lipogenesis-related genes, while its overexpression in the human liver cancer cell
line HepG2 reversed free fatty acid-induced lipid accumulation [51]. Mechanistic studies imply that
MEG3 functions as a miRNA sponge by competitively binding miR-21, leading to derepression of the
miR-21 target LRP6, inhibition of the mTOR pathway, and subsequent induction of intracellular lipid
accumulation [51]. These findings highlight the potential of MEG3 as a biomarker and therapeutic
target for NAFLD.
Expression profiling of lncRNAs of liver samples from high-fat diet fed mice identified 291
deregulated lncRNAs in a NAFLD mouse model compared to control animals [124]. Several lncRNAs,
designated as fatty liver-related lncRNA (FRL) were associated with the PPAR signaling pathway via
interactions with fatty acid binding protein 5 (Fabp5), lipoprotein lipase (Lpl) and fatty acid desaturase
2 (Fads2), respectively. The lncRNA fatty liver-related lncRNA 2 (FLRL2) is a nuclear-localized
lncRNA that is down-regulated in the NAFLD mouse model, located in the intronic region of the aryl
hydrocarbon receptor nuclear translocator-like (Arntl) gene and implicated in the regulation of Arntl
in cis [124]. Overexpression of FLRL2 in vitro alleviated lipid accumulation, inflammation, and ER
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stress in cultured mouse liver cells, whereas knockdown of FLRL2 led to accumulation of cellular
lipids [125]. Furthermore, adenovirus-mediated overexpression of FLRL2 in high fat diet-fed mice
resulted in activation of the Arntl-Sirtuin 1 pathway, inhibition of lipogenesis and reduction of hepatic
steatosis, highlighting the therapeutic potential of FLRL2 in NAFLD [125].
5. Therapeutic Targeting of lncRNAs for Treatment of Liver Disease
Several lncRNAs have been implicated in the pathogenesis HCC and NASH, as summarized
above, which makes them potential targets for RNA-based therapeutics. Effective knockdown of
disease-associated mRNAs can be achieved by using antisense oligonucleotides (ASOs) and siRNAs,
and both approaches have also been deployed to target lncRNAs in functional studies in cell culture
and in vivo [15,16]. However, the efficiency of ASO- and siRNA-based knockdown depends on the
subcellular localization of the lncRNA [126]. For example, the nuclear-localized lncRNAs MALAT1
and NEAT1 were shown to be more effectively knocked down using ASOs, whereas the cytoplasmic
lncRNAs DANCR and OIP5-AS1 were more efficiently silenced using siRNAs [126]. Thus, it is important
to determine the subcellular localization of a given lncRNA before embarking on functional studies
using either ASOs or siRNAs.
ASOs are single-stranded oligonucleotides, typically 14–20 nucleotides in length, designed to
bind and inhibit complementary RNA transcripts [127,128]. Most ASOs are chemically modified
with phosphorothioate (PS) backbone linkages to enhance the pharmacokinetic properties of ASOs
in vivo [127,128]. Moreover, improved stability and increased binding affinity are achieved using
nucleotides with sugar modifications, such as 2’-O-methoxyethyl (MOE), 2’, 4’-constrained 2’-O-ethyl
(cEt)-modified sugars, or locked nucleic acids (LNAs) [128]. Two different design paradigms are used for
ASOs: gapmer ASOs for gene knockdown, in which a central deoxynucleotide region is flanked at both
ends by modified nucleotides, e.g., 2′ MOE or LNAs, and uniformly modified mixmer ASOs that serve
as steric blockers for e.g., miRNA inhibition or splice modulation [128]. Gene knockdown is mediated
through RNase H activity, which binds and cleaves RNA/DNA heteroduplexes, whereas miRNA
inhibition and splice modulation relies on steric blocking of the miRNA guide strand or specific
splice sites, respectively, without causing RNA degradation [128]. Chemically modified ASOs have
high potential as RNA-targeted therapeutics, which is highlighted by the FDA-approved ASO-based
drugs, eteplirsen for treatment of Duchenne muscular dystrophy [129] and nusinersen for treatment of
the neurodegenerative disease spinal muscular atrophy, respectively [130]. Furthermore, ASOs are
frequently used to explore lncRNA function. For example, knockdown of MALAT1 using intravenously
injected cEt-modified gapmer ASOs in a mouse model of mammary carcinoma resulted in slower tumor
growth and reduction in metastasis [17], whereas LNA-modified gapmer ASOs have been used to
study the biological functions of the lncRNAs NEAT1 and SAMMSON, respectively [103,131]. A recent
study reported on systematic knockdown of 285 lncRNAs in human dermal fibroblasts deploying LNA
gapmer ASOs followed by quantification of cellular growth, morphological changes, and transcriptomic
responses using capped analysis of gene expression (CAGE) [132]. ASOs targeting the same lncRNAs
showed global concordance, and the molecular phenotypes assessed by CAGE recapitulated the
cellular phenotypes, while also providing information about the affected pathways [132].
Synthetic siRNA triggers can be used to engage the endogenous RNAi machinery to specifically
knock down liver-expressed transcripts, including lncRNAs. As with ASOs, knockdown by siRNAs
requires optimization for target specificity with minimized off-target effects and immunogenicity,
as well as improved nuclease resistance. This can be achieved using different sugar modifications
such as 2′-O-methyl and 2′-fluoro sugars, and by substituting phosphodiester linkages with PS
linkages [133]. Furthermore, incorporation of a 5′(E)-vinyl-phosphonate into the guide strand enhances
siRNA potency and duration of action in vivo, while the (S)-glycol nucleic acid modification in the seed
region of the guide improves potency and decreases liver toxicity [133].
The liver is amenable to both non-targeted and targeted delivery of siRNAs, and has thus attracted
a lot of interest from researchers and biopharmaceutical companies aiming to develop new therapeutic
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strategies for treatment of liver diseases. Non-targeted delivery utilizes siRNAs incorporated into
lipid nanoparticles, which accumulate in the liver [133], whereas targeted delivery of siRNAs deploys
the asialoglycoprotein receptor (ASGPR), which is expressed at high density on the surface of
hepatocytes [134]. The GalNAc oligosaccharide has high affinity towards the ASGPR receptor, enabling
rapid endocytosis and selective delivery of GalNAc-conjugated siRNAs to hepatocytes (reviewed
in [135]). Indeed, the development of GalNAc-conjugated siRNA therapeutics has resulted in recent
FDA approval of the siRNA-based drug, givosiran, for treatment of acute hepatic porphyria [136].
Furthermore, targeted delivery of triantennary GalNAc-conjugated gapmer ASOs was shown to
improve ASO potency 10-fold in mice [137], which, together with the recent advances in developing
GalNAc-conjugated siRNA drugs, sets the stage for discovering novel lncRNA-targeted therapeutics
for HCC and NASH.
6. Concluding Remarks
This review summarizes the recent findings of lncRNAs in HCC, NASH, and NAFLD.
By introducing different mode of actions of lncRNAs in the liver, we particularly focused on the
lncRNAs whose dysregulation leads to the pathogenesis of HCC and NASH. Although lncRNAs are the
focus of this review, other classes of ncRNAs apart from miRNAs and lncRNAs have also been reported
in liver disease. For example, the small ncRNA, small Cajal body-specific RNA 10 (SCARNA10),
binds to PRC2 to positively regulate TGFβ signaling in hepatic fibrogenesis [138]. Other small RNAs
and their lncRNA host genes are also reported, such as: small nucleolar RNA host gene 1 (SNHG1),
which binds to DNMT1 to inhibit p53 expression [139]; and its family member, small nucleolar RNA
host gene 20 (SNHG20), which interacts with PTEN to negatively regulate its protein level [140]. As the
number of lncRNAs is higher than that of protein-coding genes [141], more intensive, functional studies
of lncRNAs, especially using genetic manipulation (e.g., CRISPR/Cas9-based knockouts, knockout and
transgenic mice) and knockdown by ASOs or siRNAs, are needed to confirm previous findings on
lncRNAs in the liver aimed at understanding their biological mechanisms and to guide new therapeutic
approaches to combat life-threatening liver diseases, such as HCC and NASH.
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